Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsIVBXF -0.02%77 Cash Ratio is 2.17 as of Dec. 2025, which is 39% below its 10-year median of 3.55. GuruFocus rates IVBXF with a GF Score™ of 77/100 and a GF Value™ of $13.34 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,377 Biotechnology companies, Innovent Biologics ranks worse than 57.15% on this metric.
Innovent Biologics has a Cash Ratio of 2.17. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Innovent Biologics's Cash Ratio or its related term are showing as below:
IVBXF'
s Cash Ratio Range Over the Past 10 Years
Min: 1.8 Med: 3.55 Max: 23.56
Current: 2.17
During the past 10 years, Innovent Biologics's highest Cash Ratio was 23.56. The lowest was 1.80. And the median was 3.55.
IVBXF's Cash Ratio is ranked worse than 57.15% of 1377
companies
in the Biotechnology industry
Industry Median: 2.96
vs IVBXF: 2.17
Innovent Biologics (OTCPK:IVBXF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Innovent Biologics Cash Ratio Related Terms
Innovent Biologics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovent Biologics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (IVBXF) has a Cash Ratio of 2.17 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Innovent Biologics and its competitors. This is 39% below median its historical median of 3.55. Over the past decade, Innovent Biologics' Cash Ratio has ranged from 1.80 to 23.56. According to the industry distribution chart, Innovent Biologics ranks #787 out of 1377 companies in the Biotechnology industry, placing it in the top 57.2%.
Is Innovent Biologics' Cash Ratio too high?
Innovent Biologics' current Cash Ratio of 2.17 is 39% below median its 10-year median of 3.55. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 23.56. The Biotechnology industry median Cash Ratio is 2.96. Innovent Biologics' value of 2.17 is 26.7% below this industry median. Based on the distribution chart, Innovent Biologics ranks #787 out of 1377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #787 out of 1377 companies for Cash Ratio. This places Innovent Biologics in the lower half of its industry. The industry median Cash Ratio is 2.96. Innovent Biologics' value of 2.17 is 26.7% below this benchmark. Historically, Innovent Biologics' own Cash Ratio has ranged from 1.80 to 23.56 over the past decade. While the company's 10-year median is 3.55 vs. the industry median of 2.96, Innovent Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,377 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Cash Ratio of 2.17 is 26.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Cash Ratio is 2.17, which is 39% below median its own 10-year median of 3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Fairly Valued. The stock's GF Value™ is $13.34, compared to a current price of $12.37 — trading 7.3% below its estimated fair value. The current Cash Ratio is 2.17, which is 39% below median its 10-year median of 3.55 and 26.7% below the Biotechnology industry median of 2.96. Innovent Biologics' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current Cash Ratio is 2.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (IVBXF) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of $12.37 is trading 7.3% below its estimated GF Value™ of $13.34.
GuruFocus considers Innovent Biologics to be Fairly Valued.
Key valuation signals for IVBXF:
Cash Ratio: 2.17 (39% below median its 10-year median of 3.55)
GF Value™: $13.34 vs. price of $12.37 (7.3% below fair value)
Industry Position: 26.7% below the Biotechnology median (#787 of 1377)
No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
77GF Score
Get the complete analysis for IVBXF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVBXF has been successfully added to your 
